Xenon Pharmaceuticals Inc.
XENEDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
5
Next Catalyst
Aug 2026
Market Overview
Stock performance and key metrics
5 upcoming, 0 past
XEN1101
Primary Generalized Tonic-Clonic Seizures
Azetukalner
Major Depressive Disorder
XEN1101 10 mg
Major Depressive Disorder
XPF-005
Acne Vulgaris
XPF-001
Dental Pain
XPF-002
Postherpetic Neuralgia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
XEN1101 | Phase 3 | Primary Generalized Tonic-Clonic Seizures | - | - |
Azetukalner | Phase 3 | Major Depressive Disorder | - | - |
XEN1101 10 mg | Phase 2 | Major Depressive Disorder | - | - |
XPF-005 | Phase 2 | Acne Vulgaris | - | - |
XPF-001 | Phase 2 | Dental Pain | - | - |
XPF-002 | Phase 2 | Postherpetic Neuralgia | - | - |
Major Depressive Disorder
2 drugs in this indication
Acne Vulgaris
1 drug in this indication
Postherpetic Neuralgia
1 drug in this indication
Primary Generalized Tonic-Clonic Seizures
1 drug in this indication
Dental Pain
1 drug in this indication
Focal Onset Seizures
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)